Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study. Patients will be recruited during hospitalisation and be randomised to a multifaceted intervention to be delivered either 'early' (baseline) or 'late' (6 months), in a 1:1 fashion.
The study will be conducted over two phases. In phase I (0-6 months), participants randomized to 'early' will receive the intervention at baseline through 6 months, while those randomized to 'late' will receive standard-of-care and represent a control arm over this period. In phase II (6 to 12 months), those randomized to 'late' will receive the intervention at 6 months, while the 'early' group will continue in follow-up. Multifaceted Intervention The intervention aims to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s). The intervention is deliberately nested within routine clinical care to enhance the generalisability of the findings beyond a research environment and to reflect other elements of real world practice. * Patient-and-clinician 'Cholesterol score card'. This passport-sized document will serve as a communication, engagement and activation tool for patients. It will be provided to participants at the commencement of the intervention and filled out at each study follow up visit. Participants will be encouraged to fill out sections at clinically-driven follow up appointments with their treating clinicians (e.g. general practitioner, cardiologist). The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies. * Risk stratification for recurrent events. As part of the intervention, each participant will have their SMART Risk score of a recurrent event assessed using the 'U-prevent' online calculator. In addition, each participant's Lp(a) will be measured and presented graphically on a continuum of risk. Both of these risk assessments will be sent to the treating primary care clinician and a copy provided to the participant. Standard of care Participants allocated to 'late' will receive standard-of-care for the first 6 months which involves the provision of the participant's lipid profile to their nominated primary care physician/general practitioner at 6 weeks, 3 months and 6 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
2,000
Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s). The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies.
Illawarra Shoalhaven Local Health District
Wollongong, New South Wales, Australia
Proportion of patients achieving an LDL <1.4mmol/L
Proportion of patients achieving an LDL \<1.4mmol/L at 6 months. This will be determined from values obtained through local laboratory testing.
Time frame: 6 months
Proportion of patients who undergo intensification of lipid-lowering therapy
Proportion of patients who undergo intensification of lipid-lowering therapy in 6 months
Time frame: 6 months
Proportion of patients prescribed high-intensity statin
Proportion of patients prescribed a guideline-recommended high-intensity statin through 6 months
Time frame: 6 months
Proportion of patients prescribed high-intensity statin at 6 months
Proportion of patients prescribed a guideline-recommended high-intensity statin at 6 months
Time frame: 6 months
Adherence to lipid lowering therapy
Proportion of patients reporting high levels of adherence to their lipid lowering therapy at 6 months
Time frame: 6 months
Patient activation and engagement in care
Level of patient activation and engagement in their care at 6 months compared with baseline
Time frame: 6 months
Proportion of patients achieving LDL<1.4mmol/L at 12 months
Proportion of patients achieving LDL\<1.4mmol/L at 12 months
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cairns & Hinterland Hospital & Health Service
Cairns, Queensland, Australia
RECRUITINGFlinders Medical Centre
Bedford Park, South Australia, Australia
NOT_YET_RECRUITINGMonash Health
Clayton, Victoria, Australia
RECRUITINGWestern Health
Melbourne, Victoria, Australia
RECRUITINGAffiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China
RECRUITINGAll India Institute of Medical Sciences
New Delhi, India
RECRUITINGFukuoka University Hospital
Fukuoka, Japan
NOT_YET_RECRUITINGKyorin University Hospital
Mitaka, Japan
NOT_YET_RECRUITINGNational Cerebral and Cardiovascular Center
Osaka, Japan
RECRUITING...and 12 more locations